Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleExperimental Studies

Development of 36 Clones Producing Human Monoclonal Antibodies Specific to Cancer Cells and their Ability to Inhibit Cancer Cell Growth

RIEKO NAKAMURA, YOSHIRO SAIKAWA, SAIKO HOSOKAWA, KAZUMASA FUKUDA, KOICHIRO KUMAI, TETSURO KUBOTA, MASAKI KITAJIMA and YUKO KITAGAWA
Anticancer Research May 2008, 28 (3A) 1651-1657;
RIEKO NAKAMURA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YOSHIRO SAIKAWA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: saiky@sc.itc.keio.ac.jp
SAIKO HOSOKAWA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KAZUMASA FUKUDA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KOICHIRO KUMAI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TETSURO KUBOTA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MASAKI KITAJIMA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YUKO KITAGAWA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

The development of a specific antibody for cancer therapy could enable a potent strategy for overcoming cancer. As ideal immunotherapy, a human monoclonal antibody (HuMoAb) might have a useful antitumor effect without any lethal toxicities. Thirty-six unique clones producing HuMoAbs were successfully developed using tumor infiltrating lymphocytes collected from 28 patients with several malignant solid tumors. The 36 tumor-specific immunoglobins were found among 9,450 clones after 43 fusions by the conventional hybridoma method. Among these 36 HuMoAbs, 9 had a remarkable tumor-specific reaction and no reaction with normal tissues, as determined with quantum dots-streptavidin and a fluorescence microscope. The inhibition of cell proliferation by the HuMoAbs was evaluated with the MTT assay. Over 40% cell growth inhibition was confirmed with 4 of the 36 HuMoAbs. Two of the antibodies had highly-specific reactivity to carcinomatous lesions with strong growth inhibition and up to 94.3% inhibition of the control growth. In conclusion, 36 clones with HuMoAbs that have specific reactions with cancer cells were successfully established. These HuMoAbs might be utilized as either anticancer or drug delivery agents.

  • Human monoclonal antibody
  • hybridoma
  • specificity to cancer cell
  • growth inhibition

Footnotes

  • Received January 2, 2008.
  • Revision received March 11, 2008.
  • Accepted March 17, 2008.
  • Copyright© 2008 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved
PreviousNext
Back to top

In this issue

Anticancer Research: 28 (3A)
Anticancer Research
Vol. 28, Issue 3A
May-June 2008
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Development of 36 Clones Producing Human Monoclonal Antibodies Specific to Cancer Cells and their Ability to Inhibit Cancer Cell Growth
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
12 + 8 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Development of 36 Clones Producing Human Monoclonal Antibodies Specific to Cancer Cells and their Ability to Inhibit Cancer Cell Growth
RIEKO NAKAMURA, YOSHIRO SAIKAWA, SAIKO HOSOKAWA, KAZUMASA FUKUDA, KOICHIRO KUMAI, TETSURO KUBOTA, MASAKI KITAJIMA, YUKO KITAGAWA
Anticancer Research May 2008, 28 (3A) 1651-1657;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Development of 36 Clones Producing Human Monoclonal Antibodies Specific to Cancer Cells and their Ability to Inhibit Cancer Cell Growth
RIEKO NAKAMURA, YOSHIRO SAIKAWA, SAIKO HOSOKAWA, KAZUMASA FUKUDA, KOICHIRO KUMAI, TETSURO KUBOTA, MASAKI KITAJIMA, YUKO KITAGAWA
Anticancer Research May 2008, 28 (3A) 1651-1657;
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Role of the Circadian Clock Gene DEC1 in Chemosensitivity and Apoptosis in Colorectal Cancer
  • Selective Synergy of Ivermectin Combined With Recombinant Methioninase Against Colon-Cancer Cells in Contrast to Normal Fibroblasts
  • Trametinib Synergized With Abemaciclib to Inhibit Tumor Growth in Human Head and Neck Squamous Cell Carcinoma Cells
Show more Experimental Studies

Similar Articles

Anticancer Research

© 2025 Anticancer Research

Powered by HighWire